- Full-Year Forecast: Baxter has raised its adjusted diluted EPS forecast for the year to $2.93 to $3.01, up from a previous forecast of $2.88 to $2.98. The market estimate was $2.92.
- Third Quarter Forecast: The company anticipates adjusted EPS of 77 to 79 cents, surpassing the earlier estimate of 75 cents.
- Second Quarter Sales: Baxter reported sales of $3.81 billion for the second quarter, exceeding the estimate of $3.76 billion.
- Medical Products & Therapies: This segment generated sales of $1.32 billion, above the estimate of $1.31 billion.
- Healthcare Systems & Technologies: Sales reached $748 million, surpassing the estimate of $725.4 million.
- Pharmaceutical Sales: This segment reported sales of $602 million, higher than the estimated $589.7 million.
- Kidney Care Sales: Baxter reported $1.12 billion in sales for this segment, slightly above the estimate of $1.11 billion.
- Research & Development Expenses: R&D expenses were $173 million, which was somewhat higher than the estimate of $167.1 million.
- Adjusted EPS: Adjusted EPS from continuing operations was 68 cents, beating the estimate of 66 cents.
- Third-Quarter Sales Growth: For Q3 2024, the company expects reported sales growth of 3% to 4% and constant currency sales growth of 4% to 5%.
- Portfolio Expansion: Baxter continues to grow its portfolio with new technologies and unique product offerings, achieving positive results in both top-line and bottom-line figures.
- Analyst Ratings: The company’s stock has 5 buy ratings, 12 hold ratings, and 1 sell rating.
Baxter International on Smartkarma
Analyst coverage of Baxter International on Smartkarma, an independent investment research network, is positive according to Baptista Research. In their report titled “Baxter International: Driving Revenue with New Innovations and Competitive Conversions! – Major Drivers,” it was highlighted that Baxter International exceeded its first quarter 2024 earnings guidance with impressive growth rates. Strong demand and favorable pricing for a variety of products were key drivers behind this performance. The analysts at Baptista Research attribute Baxter’s success to its recent strategic transformation, which has enhanced global visibility, accountability, and verticalization.
A look at Baxter International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Baxter International shows a solid performance in dividend and value metrics, earning scores of 4 and 3 respectively. This indicates that the company is providing good returns to its investors and is reasonably priced based on its fundamental value. However, the growth and resilience scores stand at 2, suggesting room for improvement in these areas. Momentum also scored a 3, indicating a moderate level of market momentum for Baxter International.
Baxter International Inc. is a company that specializes in developing, manufacturing, and marketing products and technologies related to various medical conditions like hemophilia, immune disorders, infectious diseases, and kidney disease. Its products are utilized across a wide range of healthcare settings including hospitals, nursing homes, research laboratories, and doctors’ offices. With a mixed outlook based on the Smartkarma Smart Scores, Baxter International‘s long-term prospects may be shaped by its ability to enhance growth and resilience factors while maintaining its solid performance in dividends and value.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
